Physician profile
Natalie A Fleming
NPI 1497106165
$498.07
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.43 · 2020: $77.73 · 2022: $227 · 2023: $74.19 · 2024: $86.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $160.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $99.99 | 2022-2024 | Vaxneuvance, Gardasil 9, Vaxelis |
| Sanofi Pasteur INC. | $95.06 | 2020-2024 | |
| Ironshore Pharmaceuticals INC. | $77.93 | 2020-2022 | |
| Tris Pharma INC | $41.38 | 2020-2022 | |
| Adlon Therapeutics L.P. | $30.25 | 2019-2020 | |
| Neurelis, INC. | $29.38 | 2022 | |
| Supernus Pharmaceuticals, INC. | $23.05 | 2022 | |
| Sobi, INC | $20.11 | 2019 | |
| Abbvie INC. | $19.18 | 2022 | |
| Boston Scientific Corporation | $18.86 | 2022 | |
| Pfizer INC. | $17.09 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.16 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Fleming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.